Company	Drug	Indication

Emergent BioSolutions Inc.	BioThrax	Anthrax
Protalix BioTherapeutics Inc.	Etelyso	Type I Gaucher disease

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2026.

CINP 2026: Prenatal and adolescent stress shape brain vulnerability

BioWorld Science

Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...

Ontrack Therapeutics divulges compounds for neurodegenerative diseases

BioWorld Science

Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.

Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists

BioWorld Science

Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...

Neuracle eyes Shanghai IPO as global BCI funding surges

BioWorld

Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...

FDA Approvals In May

Related Articles